Recombinant Sj16 protein with novel activity alleviates hepatic granulomatous inflammation and fibrosis induced by Schistosoma japonicum associated with M2 macrophages in a mouse model

Parasit Vectors. 2019 Sep 23;12(1):457. doi: 10.1186/s13071-019-3697-z.

Abstract

Background: Potent granulomatous inflammation responses induced by schistosome eggs and resultant fibrosis are the primary causes of morbidity in schistosomiasis. Recombinant Sj16 (rSj16), a 16-kDa protein of Schistosoma japonicum produced in Escherichia coli, has been demonstrated to have novel immunoregulatory effects in vivo and in vitro. Thus, this study investigated the anti-inflammatory and anti-fibrotic effects of rSj16 treatment in S. japonicum-infected mice and demonstrated the immune modulation between the schistosome and the host.

Methods: Schistosoma japonicum infected mice were treated with the rSj16 protein and Sj16 peptide at different time points post-infection to assess their efficacy at the optimal time point. Sj16 peptide and/or Praziquantel (PZQ) treatments were initiated at week 5 post-infection to compare the therapeutic efficacy of each regimen. Hepatic granulomatous inflammation, fibrosis and cytokine production (pro-inflammatory, Th1, Th2, Th17 and regulatory cytokines IL-10) were detected. Moreover, M2 macrophages were measured to illuminate the mechanisms of Sj16.

Results: The rSj16 protein and Sj16 peptide had significant protective effects in S. japonicum-infected mice, as shown by decreased granuloma formation, areas of collagen deposition and inhibition of pro-inflammatory Th1, Th2 and Th17 cytokine production. These protective activities were more obvious when animals were treated with either the Sj16 protein or peptide at early stages post-infection. Interestingly, the combined treatment of PZQ and Sj16 was more effective and upregulated IL-10 production than administration of PZQ alone in infected mice. Furthermore, the Sj16 treatment alleviated the pathological effects associated with activated M2 macrophages.

Conclusions: This study demonstrates the anti-inflammatory and anti-fibrotic effects of rSj16 in schistosomiasis. Therefore, the combination of rSj16 with PZQ could be a viable and promising therapeutic strategy for schistosomiasis. In addition, this investigation provides additional information on schistosome-mediated immune modulation and host-parasite interactions.

Keywords: Fibrosis; Granulomatous inflammation; M2 macrophages; Schistosoma japonicum; rSj16.

MeSH terms

  • Animals
  • Anthelmintics / administration & dosage
  • Disease Models, Animal
  • Fibrosis / pathology
  • Fibrosis / prevention & control
  • Granuloma / pathology
  • Granuloma / prevention & control*
  • Helminth Proteins / administration & dosage
  • Helminth Proteins / metabolism*
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / metabolism*
  • Inflammation / pathology
  • Inflammation / prevention & control
  • Liver / pathology*
  • Macrophages / immunology*
  • Mice
  • Praziquantel / administration & dosage
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / metabolism
  • Schistosomiasis japonica / pathology*
  • Treatment Outcome

Substances

  • Anthelmintics
  • Helminth Proteins
  • Immunologic Factors
  • Recombinant Proteins
  • Praziquantel